IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 2308 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  NAVIGATE Here 
    Next article
    Previous article
    Table of Contents

 RESOURCE Links
    Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed3699    
    Printed45    
    Emailed2    
    PDF Downloaded0    
    Comments [Add]    

Recommend this journal

 

 ORIGINAL ARTICLE
Year : 1997  |  Volume : 63  |  Issue : 6  |  Page : 347--353

Enhanced Toxicity Potential of a Regimen on Addition of Doxorubicin in Combination Chemo-therapy


Correspondence Address:
A M Vimala


Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 20944376

Rights and PermissionsRights and Permissions

A comparative study of cutaneous toxicities of two different commonly used combination chemotherapeutic regimens was conducted on 16 patients of non-Hodgkin's lymphoma. The common drugs in the two regimens were cyclophosphamide, vincristine and prednisone. One of the regimens which was administered to 10 patients, included doxorubicin as an additional drug. This combination is preferred in high grade malignancy. However, the addition of doxorubicin resulted in enhanced severity and multiplicity of cutaneous manifestations. If it is possible to choose between two or more regimens for a given malignancy, the risk-benefit ratio can be weighed to choose the appropriate and least toxic drugs.






[FULL TEXT] [PDF Not available]*


        
Print this article     Email this article

Online since 15th March '04
Published by Wolters Kluwer - Medknow